Form 4: Neurocrine Biosciences Chief Medical Officer Receives Stock Options and Restricted Stock Units

Neurocrine Biosciences' Chief Medical Officer, Eiry Roberts, was granted stock options and restricted stock units as part of their compensation.

Summary

• Eiry Roberts, the Chief Medical Officer of Neurocrine Biosciences, received 27,770 stock options and 5,487 restricted stock units on December 17, 2024.
• The stock options have an exercise price of $136.69 and expire on December 17, 2034.
• The restricted stock units will vest in four equal installments on February 13th of 2025, 2026, 2027, and 2028.
• The stock options will vest 1/4 on February 13, 2025, and then 1/48th each month starting March 13, 2025, fully vesting on February 13, 2028.

Sentiment

Score: 7

Explanation: The document reflects a standard compensation practice, which is generally positive for aligning executive interests with shareholders. There are no negative implications.

Positives

• The grant of stock options and restricted stock units aligns the Chief Medical Officer's interests with those of the shareholders.
• The vesting schedule of the stock options and restricted stock units encourages long-term commitment from the Chief Medical Officer.

Future Outlook

This document does not contain any forward-looking statements or guidance.

Industry Context

The granting of stock options and restricted stock units is a common practice in the biotechnology industry to incentivize and retain key executives.

Comparison to Industry Standards

• Stock option and restricted stock unit grants are standard compensation practices for executives in the biotech industry, aligning with companies like Amgen, Biogen, and Gilead Sciences.
• The vesting schedules described are typical, with multi-year vesting periods to encourage long-term commitment, similar to what is seen in other biotech firms.
• The exercise price of $136.69 is relevant to the current market price of Neurocrine Biosciences stock, which is not provided in this document.

Stakeholder Impact

• The grant of equity to the Chief Medical Officer aligns their interests with shareholders, potentially leading to better performance and increased shareholder value.
• The vesting schedule encourages long-term commitment from the executive, which can benefit the company and its stakeholders.

Key Dates

Keywords

Neurocrine Biosciences, Stock Options, Restricted Stock Units, Eiry Roberts, Chief Medical Officer, Equity Compensation, Vesting